The AAR2 Knockout HT29 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population targeting the AAR2 gene in the HT29 human colorectal adenocarcinoma line. This heterogeneous pool captures multiple editing events, establishing a robust loss-of-function model for investigating spliceosome assembly and pre-mRNA splicing without requiring clonal isolation. The polyclonal format allows population-level phenotypic analyses while preserving experimental throughput.
The parental HT29 cell line is a well-characterized colorectal adenocarcinoma model harboring inactivating mutations in APC and TP53 and the oncogenic BRAF V600E substitution. These genetic alterations drive constitutive Wnt/??-catenin signaling and MAPK pathway hyperactivation, recapitulating key oncogenic features of colonic epithelium. HT29 cells form polarized monolayers and are extensively applied in studies of colorectal cancer biology, tumor progression, and therapeutic response.
AAR2 encodes a dedicated chaperone and assembly factor essential for U5 snRNP biogenesis. It directly interacts with core U5 components including PRPF8, SNRNP200, and EFTUD2, facilitating PRPF8 folding and promoting spliceosome maturation. AAR2 expression is regulated by MYC-dependent transcriptional programs and is integrated into the broader spliceosome component synthesis network. Disruption of AAR2 impairs U5 snRNP assembly, leading to widespread splicing defects that preferentially affect pre-mRNAs encoding cell cycle and apoptosis regulators. Downstream consequences include aberrant splicing of proliferation- and survival-associated transcripts, linking AAR2 loss to cell cycle arrest and reduced viability.
In the HT29 context, AAR2 knockout enables dissection of U5 snRNP dependency in BRAF-mutant colorectal cancer. Colorectal tumors frequently exhibit splicing abnormalities, and this polyclonal knockout model mirrors the heterogeneity of tumor cell responses to spliceosome stress. The interplay between AAR2 loss and mutant p53 and hyperactive MAPK signaling can reveal synthetic lethal interactions, identifying vulnerabilities that may be exploited by spliceosome-targeted therapies.
Typical applications include RNA sequencing with isoform-aware analysis for transcriptome-wide splicing profiling, RT-PCR validation of specific splice variants, and western blotting for AAR2 and U5 snRNP proteins such as PRPF8 and SNRNP200. Cell viability and apoptosis assays quantify growth defects, while co-treatment with spliceosome inhibitors (e.g., SF3B modulators) enables screening for synthetic lethality or drug sensitization. These approaches support mechanistic dissection of spliceosome function in colorectal cancer and facilitate discovery of novel therapeutic strategies. For additional product information, please contact Ascent Research.
